Life Science Today
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Pfizer + Biohaven, Regulators, Lilly, BridgeBio + BMS
An $11.6B yes, $11.7B delay, drop the AIC with GLP, and a billion bio-bucks
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Pfizer + Biohaven
Regulators
Lilly
BridgeBio + BMS
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Zymeworks, Phathom, Catalyst, CenExel, Intercept + Advanz
Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal deal
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Zymeworks
Phathom
Catalyst
CenExel
Intercept + Advanz
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Merck, Sanofi, J&J, ThermoFisher, Novo Nordisk, Eli Lilly
Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle looms
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Merck
Sanofi
J&J
ThermoFisher
Novo Nordisk
Eli Lilly
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Orasis, Reify, Blackrock + MindX
Drops for reading, a $220M raise, and an acquisition straight out of the movies
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Orasis
Reify
Blackrock + MindX
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
FDA, Antares + Halozyme, GSK + Sierra, Ansa
The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA.
Find out more at
https://LifeScienceTodayPodcast.com
Story References
FDA
Antares + Halozyme
GSK + Sierra
Ansa Biotechnologies
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Pfizer + ReViral, Novartis, Charles River + Explora Labs
Viral therapies, rare disease approvals, and lab space premiums
Find out more at
https://LifeScienceTodayPodcast.com
Story References
Pfizer + ReViral
Novartis
Charles River + Explora Labs
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Responses